Foxx Development Holdings Inc. (NASDAQ:FOXX – Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 24,806 shares, a drop of 60.2% from the February 12th total of 62,275 shares. Based on an average daily volume of 12,207 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.5% of the company’s shares are sold short. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 12,207 shares, the days-to-cover ratio is presently 2.0 days.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Foxx Development in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Foxx Development has a consensus rating of “Sell”.
View Our Latest Report on FOXX
Foxx Development Price Performance
Foxx Development (NASDAQ:FOXX – Get Free Report) last issued its quarterly earnings results on Friday, February 13th. The company reported ($0.62) earnings per share (EPS) for the quarter. The business had revenue of $16.72 million during the quarter.
Insider Activity
In other news, CTO James Liao sold 9,716 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $4.61, for a total value of $44,790.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 31.60% of the company’s stock.
Institutional Investors Weigh In On Foxx Development
An institutional investor recently bought a new position in Foxx Development stock. Citadel Advisors LLC purchased a new stake in Foxx Development Holdings Inc. (NASDAQ:FOXX – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned approximately 0.18% of Foxx Development at the end of the most recent quarter. 60.44% of the stock is owned by institutional investors and hedge funds.
Foxx Development Company Profile
Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.
Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.
Featured Articles
- Five stocks we like better than Foxx Development
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Foxx Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foxx Development and related companies with MarketBeat.com's FREE daily email newsletter.
